PsyLabs Closes Swap, Holds 49.75% of Psyence Biomedical at US$6.00/Share
PBM has more than doubled off its 52-week low of $1.92.
Summary
Psyence Labs closed its share-for-share swap, lifting its stake in Psyence Biomedical to 49.75% via 1,497,500 shares issued at a deemed US$6.00 each, with standstill restrictions attached.
Key Events · Ownership and Investor Activity · PBM
-
Swap Closed, 49.75% Stake
Psyence Labs acquired 1,497,500 common shares on October 1, 2026, bringing its total to 2,643,659 shares, or 49.75% of the 5,314,048 shares outstanding.
-
Deemed Price US$6.00 Per Share
The shares were issued at a deemed price of US$6.00 each for US$8,985,000 in non-cash consideration — 3,473 PsyLabs ordinary shares valued at a US$60 million implied equity valuation. No cash was paid by any party.
-
Control-Person Status and Standstill
PsyLabs may be deemed an affiliate and control person of the Issuer, and agreed to standstill restrictions barring further acquisitions, proxy activity, or board influence while it holds any shares.
-
Unregistered Shares With Resale Limits
The Additional Shares were issued under Section 4(a)(2)/Regulation S, carry restrictive legends, and may face additional resale limits because PsyLabs may be an affiliate.
Analysis · PBM · Life Sciences
Psyence Labs Ltd., already the company's largest shareholder, completed the share-for-share swap announced on September 21 and now holds 2,643,659 common shares — 49.75% of the 5,314,048 shares outstanding. The 1,497,500 new shares were issued at a deemed price of US$6.00 each (US$8,985,000 non-cash), well above the current $4.00 market price, in exchange for 3,473 PsyLabs ordinary shares valued at a US$60 million implied equity valuation. No cash changed hands. The stake is large enough that PsyLabs may be deemed an affiliate and control person, and it agreed to broad standstill restrictions — no further buying, no proxy activity, no board influence — for as long as it holds any shares. That caps the risk of an activist campaign but also means the company's largest holder is locked in place, and the unregistered shares carry resale restrictions.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.4% of the 1757 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8M. The 52-week trading range was $1.92 to $22.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.